Antares Pharma Inc. (ATRS)

3.03
0.06 2.00
NASDAQ : Health Technology
Prev Close 2.97
Open 2.97
Day Low/High 2.90 / 3.08
52 Wk Low/High 2.53 / 3.96
Volume 937.73K
Avg Volume 1.08M
Exchange NASDAQ
Shares Outstanding 162.62M
Market Cap 494.36M
P/E Ratio N/A
Div & Yield N.A. (N.A)

Stocks Under $10 Weekly Summary

We added to one position last week as as the small-cap heavy Russell 2000 dipped.

Stocks Under $10 Weekly Summary

We added to one position and initiated another during a shortened holiday week.

Stocks Under $10 Weekly Summary

We initiated a new position and added to a couple of others as we closed the books on the second quarter.

Interesting ATRS Put And Call Options For February 2020

Interesting ATRS Put And Call Options For February 2020

Investors in Antares Pharma Inc. saw new options begin trading this week, for the February 2020 expiration.

Stocks Under $10 Weekly Summary

Last week we started two new positions, trimmed a winner and exited another name as the markets moved higher across the board.

Stocks Under $10 Weekly Summary

With the market rising last week, we saw favorable action in several of our holdings and booked some hefty gains in one name.

Stocks Under $10 Weekly Summary

With the market rebounding, the majority of our positions rose week over week.

Stocks Under $10 Weekly Summary

During the week, we exited our position in KushCo Holdings and initiated Antares Pharma.

An Initiation and an Exit

We will close out KushCo Holdings, largely replacing it with an initial position in Antares Pharma.

Adding a Specialty Pharma Name to the Bullpen

There’s enough to like about Antares Pharma to keep an eye on it.

First Week Of June 21st Options Trading For Antares Pharma (ATRS)

First Week Of June 21st Options Trading For Antares Pharma (ATRS)

Investors in Antares Pharma Inc. saw new options begin trading this week, for the June 21st expiration.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALRM, ATRS, CCK, CGC, FHN, FLGT, FND, GIFI, GTS, IMKTA, IONS, IROQ, LAWS, LEG, MANH, MOFG, NMFC, NPTN, NWN, RUN, VAC, WAL, XRAY Downgrades: ACHC, CNCE, HCI, ORBC, VMW Initiations: ALTR, FNKO, SE Read on to get TheStreet Quant Ratings' detailed report:

Noteworthy Tuesday Option Activity: ATRS, ADI, CMTL

Noteworthy Tuesday Option Activity: ATRS, ADI, CMTL

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Antares Pharma Inc. , where a total volume of 6,257 contracts has been traded thus far today, a contract volume which is representative of approximately 625,700 underlying shares (given that every 1 contract represents 100 underlying shares).

Antares Pharma Provides XYOSTED™ Regulatory Update

Antares Pharma Provides XYOSTED™ Regulatory Update

Complete Response Resubmission Accepted - PDUFA Date September 29, 2018

Antares Pharma Provides XYOSTED™ Regulatory Update

Antares Pharma Provides XYOSTED™ Regulatory Update

The Company Anticipates Second Quarter 2018 Resubmission

Antares Pharma Reports Fourth Quarter And Full Year 2017 Operating And Financial Results

Antares Pharma Reports Fourth Quarter And Full Year 2017 Operating And Financial Results

Record Annual Revenue of $54.5 Million

First Week of April 20th Options Trading For Antares Pharma (ATRS)

First Week of April 20th Options Trading For Antares Pharma (ATRS)

Investors in Antares Pharma Inc. saw new options become available this week, for the April 20th expiration.

Antares Pharma Announces FDA Approval Of Partner's Product Utilizing Our QuickShot Auto Injector

Antares Pharma Announces FDA Approval Of Partner's Product Utilizing Our QuickShot Auto Injector

AMAG Pharmaceuticals Makena® Subcutaneous Auto-Injector Approved To Reduce The Risk Of Preterm Birth In Certain At-Risk Women

Antares Pharma Announces FDA Approval Of Partner's Product Utilizing Our QuickShot Auto Injector

Antares Pharma Announces FDA Approval Of Partner's Product Utilizing Our QuickShot Auto Injector

AMAG Pharmaceuticals Makena® Subcutaneous Auto-Injector Approved To Reduce The Risk Of Preterm Birth In Certain At-Risk Women

Glancy Prongay & Murray Reminds Investors Of The December 22, 2017 Deadline In The Class Action Lawsuit Against Antares Pharma, Inc. (ATRS)

Glancy Prongay & Murray Reminds Investors Of The December 22, 2017 Deadline In The Class Action Lawsuit Against Antares Pharma, Inc. (ATRS)

Glancy Prongay & Murray LLP ("GPM") reminds investors of the December 22, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Antares Pharma, Inc.

ANTARES LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Antares Pharma, Inc. To Contact The Firm

ANTARES LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Antares Pharma, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Antares Pharma, Inc.

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of December 22nd Lead Plaintiff Deadline In Securities Class Action Against Antares Pharma, Inc. (ATRS)

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of December 22nd Lead Plaintiff Deadline In Securities Class Action Against Antares Pharma, Inc. (ATRS)

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, reminds investors that a class action lawsuit has been filed against Antares Pharma, Inc.

TheStreet Quant Rating: C (Hold)